4.67 USD
-0.01 (-0.21%)
4.5001 USD
-0.17 (-3.64%)
Overall EKSO gets a fundamental rating of 2 out of 10. We evaluated EKSO against 187 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of EKSO have multiple concerns. While showing a medium growth rate, EKSO is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
EKSO had negative earnings in the past year.
EKSO had a negative operating cash flow in the past year.
EKSO had negative earnings in each of the past 5 years.
In the past 5 years EKSO always reported negative operating cash flow.
1.2 Ratios
EKSO has a worse Return On Assets (-49.21%) than 65.78% of its industry peers.
EKSO's Return On Equity of -110.14% is on the low side compared to the rest of the industry. EKSO is outperformed by 64.17% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -49.21% | ||
| ROE | -110.14% | ||
| ROIC | N/A |
ROA(3y)-43.98%
ROA(5y)-46.15%
ROE(3y)-89.67%
ROE(5y)-131.07%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
EKSO has a Gross Margin of 53.48%. This is comparable to the rest of the industry: EKSO outperforms 48.66% of its industry peers.
In the last couple of years the Gross Margin of EKSO has grown nicely.
EKSO does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 53.48% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.01%
GM growth 5Y1.79%
2. Health
2.1 Basic Checks
EKSO does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, EKSO has more shares outstanding
The number of shares outstanding for EKSO has been increased compared to 5 years ago.
Compared to 1 year ago, EKSO has an improved debt to assets ratio.
2.2 Solvency
EKSO has an Altman-Z score of -16.51. This is a bad value and indicates that EKSO is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -16.51, EKSO is not doing good in the industry: 87.17% of the companies in the same industry are doing better.
A Debt/Equity ratio of 0.31 indicates that EKSO is not too dependend on debt financing.
EKSO has a Debt to Equity ratio (0.31) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.31 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -16.51 |
ROIC/WACCN/A
WACC7.16%
2.3 Liquidity
EKSO has a Current Ratio of 1.66. This is a normal value and indicates that EKSO is financially healthy and should not expect problems in meeting its short term obligations.
EKSO's Current ratio of 1.66 is on the low side compared to the rest of the industry. EKSO is outperformed by 71.12% of its industry peers.
A Quick Ratio of 1.09 indicates that EKSO should not have too much problems paying its short term obligations.
With a Quick ratio value of 1.09, EKSO is not doing good in the industry: 73.80% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.66 | ||
| Quick Ratio | 1.09 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 41.74% over the past year.
EKSO shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -16.59%.
Measured over the past years, EKSO shows a small growth in Revenue. The Revenue has been growing by 5.19% on average per year.
EPS 1Y (TTM)41.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%64%
Revenue 1Y (TTM)-16.59%
Revenue growth 3Y16.8%
Revenue growth 5Y5.19%
Sales Q2Q%2.37%
3.2 Future
EKSO is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 16.47% yearly.
Based on estimates for the next years, EKSO will show a quite strong growth in Revenue. The Revenue will grow by 18.01% on average per year.
EPS Next Y59.2%
EPS Next 2Y38.35%
EPS Next 3Y20.9%
EPS Next 5Y16.47%
Revenue Next Year-17.71%
Revenue Next 2Y12.81%
Revenue Next 3Y18.01%
Revenue Next 5YN/A
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
EKSO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year EKSO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as EKSO's earnings are expected to grow with 20.90% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y38.35%
EPS Next 3Y20.9%
5. Dividend
5.1 Amount
No dividends for EKSO!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
4.67
-0.01 (-0.21%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners7.7%
Inst Owner Change198.37%
Ins Owners6.63%
Ins Owner Change0.44%
Market Cap15.83M
Revenue(TTM)14.75M
Net Income(TTM)-10.66M
Analysts82.5
Price Target7.91 (69.38%)
Short Float %2.9%
Short Ratio1.97
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)31.86%
Min EPS beat(2)9.95%
Max EPS beat(2)53.76%
EPS beat(4)2
Avg EPS beat(4)-3.7%
Min EPS beat(4)-71.57%
Max EPS beat(4)53.76%
EPS beat(8)4
Avg EPS beat(8)-15.61%
EPS beat(12)5
Avg EPS beat(12)-10.05%
EPS beat(16)8
Avg EPS beat(16)-7.85%
Revenue beat(2)0
Avg Revenue beat(2)-28.94%
Min Revenue beat(2)-53.24%
Max Revenue beat(2)-4.65%
Revenue beat(4)0
Avg Revenue beat(4)-21.89%
Min Revenue beat(4)-53.24%
Max Revenue beat(4)-1.24%
Revenue beat(8)0
Avg Revenue beat(8)-18.43%
Revenue beat(12)3
Avg Revenue beat(12)-9.03%
Revenue beat(16)4
Avg Revenue beat(16)-6.14%
PT rev (1m)-77.7%
PT rev (3m)-77.7%
EPS NQ rev (1m)20.97%
EPS NQ rev (3m)20.97%
EPS NY rev (1m)22.97%
EPS NY rev (3m)36.67%
Revenue NQ rev (1m)-2.66%
Revenue NQ rev (3m)-8.84%
Revenue NY rev (1m)-11.46%
Revenue NY rev (3m)-11.46%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 1.07 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.64 | ||
| P/tB | 3.11 | ||
| EV/EBITDA | N/A |
EPS(TTM)-5.68
EYN/A
EPS(NY)-0.73
Fwd EYN/A
FCF(TTM)-2.65
FCFYN/A
OCF(TTM)-2.63
OCFYN/A
SpS4.35
BVpS2.86
TBVpS1.5
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -49.21% | ||
| ROE | -110.14% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 53.48% | ||
| FCFM | N/A |
ROA(3y)-43.98%
ROA(5y)-46.15%
ROE(3y)-89.67%
ROE(5y)-131.07%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.01%
GM growth 5Y1.79%
F-Score4
Asset Turnover0.68
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.31 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 5.46% | ||
| Cap/Sales | 0.56% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.66 | ||
| Quick Ratio | 1.09 | ||
| Altman-Z | -16.51 |
F-Score4
WACC7.16%
ROIC/WACCN/A
Cap/Depr(3y)10.97%
Cap/Depr(5y)8.72%
Cap/Sales(3y)0.85%
Cap/Sales(5y)0.61%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)41.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%64%
EPS Next Y59.2%
EPS Next 2Y38.35%
EPS Next 3Y20.9%
EPS Next 5Y16.47%
Revenue 1Y (TTM)-16.59%
Revenue growth 3Y16.8%
Revenue growth 5Y5.19%
Sales Q2Q%2.37%
Revenue Next Year-17.71%
Revenue Next 2Y12.81%
Revenue Next 3Y18.01%
Revenue Next 5YN/A
EBIT growth 1Y6.95%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y37.07%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y36.95%
OCF growth 3YN/A
OCF growth 5YN/A
EKSO BIONICS HOLDINGS INC / EKSO FAQ
Can you provide the ChartMill fundamental rating for EKSO BIONICS HOLDINGS INC?
ChartMill assigns a fundamental rating of 2 / 10 to EKSO.
What is the valuation status of EKSO BIONICS HOLDINGS INC (EKSO) stock?
ChartMill assigns a valuation rating of 1 / 10 to EKSO BIONICS HOLDINGS INC (EKSO). This can be considered as Overvalued.
What is the profitability of EKSO stock?
EKSO BIONICS HOLDINGS INC (EKSO) has a profitability rating of 1 / 10.
What is the expected EPS growth for EKSO BIONICS HOLDINGS INC (EKSO) stock?
The Earnings per Share (EPS) of EKSO BIONICS HOLDINGS INC (EKSO) is expected to grow by 59.2% in the next year.